Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Endocrinology and Metabolism Clinics of North America|June 4, 2014
How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin levelRossella Elisei, Laura Agate, David Viola, et al.
Thyroid : Official Journal of the American Thyroid Association|June 11, 2013
Prognostic factors in papillary microcarcinoma with emphasis on histologic subtyping: a clinicopathologic study of 148 casesRonald Ghossein, Ian Ganly, Agnese Biagini, et al.
The Journal of Clinical Endocrinology and Metabolism|February 19, 2009
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomyPaolo Miccoli, Aldo Pinchera, Gabriele Materazzi, et al.
The Journal of Clinical Endocrinology and Metabolism|August 7, 2008
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up studyRossella Elisei, Clara Ugolini, David Viola, et al.
The Laryngoscope|April 21, 2015
RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification systemRebecca Zeuren, Agnese Biagini, Ravinder K Grewal, et al.
Oncotargets and Therapy|November 2, 2016
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancerLoredana Lorusso, Letizia Pieruzzi, Agnese Biagini, et al.
The Journal of Clinical Endocrinology and Metabolism|April 30, 2013
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-upEleonora Molinaro, Carlotta Giani, Laura Agate, et al.
Nature Reviews. Endocrinology|July 15, 2017
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapiesEleonora Molinaro, Cristina Romei, Agnese Biagini, et al.
Clinical Endocrinology|December 3, 2014
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?Cristina Romei, Alessia Tacito, Eleonora Molinaro, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2012
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort studyRossella Elisei, David Viola, Liborio Torregrossa, et al.
Pageof 2